Wegovy is an FDA-approved injectable medication containing semaglutide that helps people lose weight by reducing appetite and increasing feelings of fullness. It belongs to a class of drugs called GLP-1 receptor agonists, originally developed to treat type 2 diabetes. Unlike temporary weight loss solutions, Wegovy addresses the underlying biological mechanisms that drive hunger and weight gain.
Semaglutide works by mimicking glucagon-like peptide-1 (GLP-1), a hormone that regulates blood sugar, appetite, and digestion. When injected weekly, it signals your brain that you’re satisfied with smaller portions of food. This mechanism is fundamentally different from appetite suppressants that simply increase energy or reduce hunger for a few hours.
Wegovy is prescribed for adults with:
Studies show Wegovy users lose an average of 15-22% of their body weight over 68 weeks. Many patients experience significant weight loss within 3-6 months of starting treatment. This represents a substantial improvement compared to lifestyle changes alone, which typically result in 3-5% weight loss.
The medication works through multiple mechanisms: it increases satiety signals to your brain, reduces hunger hormones (especially ghrelin), and slows gastric emptying so you feel fuller longer. This combination helps you naturally eat less without the mental struggle of traditional dieting.
